UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Human immunodeficiency virus antibodies and the vaccine problem.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Chiodi F, Weiss RA
  • Publication date:
    05/2014
  • Pagination:
    444, 455
  • Journal:
    J Intern Med
  • Volume:
    275
  • Issue:
    5
  • Status:
    Published
  • Country:
    England
  • Language:
    eng
  • Keywords:
    antibody, envelope glycoprotein, human immunodeficiency virus, vaccine, AIDS Vaccines, Adjuvants, Immunologic, Animals, B-Lymphocytes, Clinical Trials as Topic, Disease Models, Animal, Epitopes, B-Lymphocyte, Forecasting, HIV Antibodies, HIV Infections, HIV-1, Humans, Immunity, Cellular, Immunity, Humoral, Immunity, Mucosal, Technology, Pharmaceutical, Vaccines, Synthetic, Viral Envelope Proteins
Abstract
Despite the great advances made in controlling human immunodeficiency virus type 1 (HIV-1) infection with antiretroviral drug treatment, a safe and efficacious HIV vaccine has yet to be developed. Here, we discuss why clinical trials and vaccine development for HIV have so far been disappointing, with an emphasis on the lack of protective antibodies. We review approaches for developing appropriate HIV immunogens and the stimulation of long-lasting B-cell responses with antibody maturation. We conclude that candidate reagents in the pipeline for HIV vaccine development are unlikely to be particularly effective. Although the major funders of HIV vaccine research and development are placing increasing emphasis on clinical product development, a genuine breakthrough in preventing HIV infection through vaccines is more likely to come from novel immunogen research.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Div of Infection & Immunity
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by